본문 바로가기
태국 코로나 백신, 치료제

AZ백신 2차 접종후 감염 자료. 인도 케랄라

by 태국은 2021. 6. 20.

인도 케랄라에 있는 한 병원의 데이터 입니다

 

이 지역에서 델타 바이러스가 발생했을 때

이미 두 번의 AZ를 투여받은

1,322 명의 의료진의 자료를 수집했습니다.

 

모든 사람이 2 차 접종을 받고나서

최소 2 주 후에 데이터를 수집 한 결과

108 명이 감염 되었습니다 (감염율 8.2 %)

환자의 평균 연령은 약 32 세 였으며

AZ 백신의 두 번 투여 간격은 평균 30 일 또는

4 주 였고, 대부분의 환자는 건강했습니다.

당뇨병, 고혈압, 폐 질환 또는 암과 같은

위험에 처한 기저 질환 없음

 

여기서 기억해야 할것은

- 평균연령 32 세

- 병원 의료진

- 기저 질환의 위험이 아무도 없었다 입니다. 

 

만약에 노인 그룹 이라도 같은 결과 였을까요?

누구도 장담 못할 겁니다

 


흥미롭게도 108 명의 환자의 다수 증상은

발열 (57.4 %)로 밝혀졌습니다.

인후통, 근육통 7 명 (6.4 %)

그 외는 증상없었다고

(*이부분은 태국어 번역 에러 일수도 있습니다)

중증 증상을 보인 6 명은

병원에 입원해야 했지만

산소 나 인공 호흡기가 필요하지 않았습니다

(사망자도 없습니다)


결론적으로 이 연구는

AZ 백신을 2 회 접종 한 사람에게도

감염이 발견 될 수 있지만 증상은 경미합니다.

이것은 접종받은 백신의 면역력 때문일 수 있습니다.

*** 흥미로운 것은 첫 번째와 두 번째 접종이

4 주 간격으로 이루어지며 최대 4 개월을(16주)

기다릴 필요가 없다는 것입니다.

 

 

30 วัน หรือ  4 สัปดาห์ ผู้ป่วยส่วนใหญ่มีสุขภาพดี ไม่มีโรคประจำตัวที่เป็นความเสี่ยง เช่น เบาหวาน ความดันสูง โรคปอด หรือ มะเร็ง
ข้อมูลที่น่าสนใจคือ อาการป่วยของ 108 คนดังกล่าว พบว่า เป็นไข้ (57.4%)  ตามมาด้วย เจ็บคอ ปวดกล้ามเนื้อ มี 7 คน หรือ 6.4% ที่ไม่มีอาการ และ มี 6 คน ที่มีอาการหนักต้องเข้ารักษาตัวในโรงพยาบาลแต่ไม่จำเป็นต้องใช้ออกซิเจน หรือ เครื่องช่วยหายใจ ... ไม่มีผู้ป่วยเสียชีวิต
โดยสรุปจากการศึกษานี้คือ การติดเชื้อซ้ำในคนที่ได้รับวัคซีน AZ 2 โดส สามารถพบได้ แต่อาการไม่รุนแรง ซึ่งน่าจะมาจากภูมิคุ้มกันจากวัคซีนที่ได้รับ ***ข้อมูลที่น่าสนใจคือ เข็มแรก และ เข็มสอง ให้ห่างกันเพียง 4 อาทิตย์ ไม่ต้องรอยาวถึง 4 เดือน ... ผลที่ออกมาผมว่าดูไม่ขี้เหร่เลย เมื่อเทียบกับความเสี่ยงจากวัคซีนโดสเดียว

 

 

 

아래는 국제의학저널에 실린

연구자료의 원본을 볼수 있는 링크 입니다

 

https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab167/6297399?login=true&fbclid=IwAR2XC-0l8pXfP9j2IRHNp3PQWjbq_12rrIr_Eb9mg0UuZw4evc2liE-bgGY 

 

Correspondence: Breakthrough COVID-19 Infections among Health Care Workers after Two Doses of ChAdOx1 nCoV-19 Vaccine

Vettakkara Kandy Muhammed Niyas, Rajalakshmi Arjun; Correspondence: Breakthrough COVID-19 Infections among Health Care Workers after Two Doses of ChAdOx1 nCoV-1

academic.oup.com

 

댓글